

Estimated Relative Adverse Effect Profiles Between Second-generation Antipsychotic Medications.

	Weight Gain	Hyperprolactin/ Sexual Dysfunction	Metabolic Syndrome*	Sedation	Tardive Dyskinesia	Acute Parkinsonism	Akathisia/ Restlessness	QTc Prolongation
Amisulpride	0/+	+++	0/+	0/+	0/+	+	+	++
Aripiprazole	0	0	0/+	0/+	0/+	+	++	0
Asenapine	+	+	0/+	+	0/+	++	+	+
Brexiprazole	0	0	0/+	0/+	0/+	+	++	0
Cariprazine	0/+	0	0/+	0/+	0/+	++	++	0
Clozapine[^]	+++	0	+++	+++	0	0	+	+
Iloperidone	+/>++	0/+	+	0/+	0/+	0/+	0/+	0/+
Lumateperone^{^^}								
Lurasidone	0/+	+	0/+	+/>++	0/+	++	+/>++	0/+
Olanzapine	+++	+	+++	+/>++	0/+	0/+	+	+
Paliperidone	++	+++	+	0/+	0/+	++	+	+
Quetiapine	++	0	++	++	0/+	0	+	+
Risperidone	++	+++	+	+	0/+	++	++	++
Sertindole	++	+	+	0/+	0/+	0/+	+	++
Ziprasidone	0/+	+	0/+	+	0/+	+	+/>++	++

Notes: 0 = neutral; +, ++, and +++ indicate greater comparative, but not absolute, side effect relevance between the drugs.

*Includes waist circumference, dyslipidemia, diabetes mellitus, and hypertension.

[^]Monitor for unique adverse effects with clozapine, such as neutropenia, sialorrhea and seizures.

^{^^}Approved by FDA in 2019. Relative side effect comparison not available.

Adapted from: Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. *Ther Clin Risk Manag.* 2017;13:757-777. doi: 10.2147/TCRM.S117321.